Guard Therapeutics
1.64 SEK
+2.50 %
Less than 1K followers
GUARD
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+2.50 %
-17.59 %
+11.56 %
+21.93 %
-92.90 %
-91.18 %
-97.20 %
-97.62 %
-99.90 %
Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.
Read moreMarket cap
33.07M SEK
Turnover
69.81K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20/2
2026
Annual report '25
11/5
2026
Interim report Q1'26
18/5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Guard Therapeutics meddelar idag förändringar i bolagets ledningsgrupp
Guard Therapeutics Announces Changes to the Company’s Management Team
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools